



## Abuse of sulfonylureas: Is factitious hypoglycemia a cause for concern?

Mayyada Wazaify<sup>1</sup> · Leen Abushams<sup>1</sup> · Marie Claire Van Hout<sup>2</sup>

Received: 6 August 2018 / Accepted: 10 December 2018 / Published online: 4 January 2019  
© Springer Nature Switzerland AG 2019

### Abstract

Several prescription and nonprescription drugs are liable for abuse. However, oral hypoglycemic agents are among the most benign and low-risk drugs in terms of abuse liability. This *commentary* intends to raise awareness regarding the abuse of a particular type of oral hypoglycemic agent, namely sulfonylurea drugs, used to experience mental-altering effects for its euphoric “hypoglycemic rush.” Information is available on discussion fora online where people exchange their experiences. Moreover, several case reports have been published and described the liability for abuse of sulfonylurea drugs. This article intends to shed the light on this phenomenon in light of the available literature, attempting to explain the possible scientific basis for it. In addition, it highlights the need for health professional awareness and vigilance for this form of drug diversion.

**Keywords** Abuse · Euphoria · Factitious hypoglycemia · Prescription drug abuse · Sulfonylurea

### Impacts on practice

- Clinicians should be aware of the underestimated, under-researched issue of hypoglycemic drug abuse.
- To avoid the misuse of hypoglycaemic medication, the legislative authorities in some countries should limit access to sulfonylurea drugs to be available strictly on prescription.

The aim of writing this commentary is to shed the light on a briefly reported and dated form of intentional drug intoxication known as “factitious hypoglycemia” [1, 2] which appears to be reemerging in recent times [1, 3]. We refer to the phenomenon of abuse of a particular type of oral hypoglycemic agents, namely sulfonylurea drugs, used to experience mental-altering effects for its euphoric “hypoglycemic rush” [1]. We utilize the definition of abuse whereby intentional use of pharmaceutical medicines is for nonmedical purposes, rather than accidental overdose [4]. Anecdotal

web discussions [5] and case reports of Marchetti et al. [6] and Svirski and Edoute [7] center on the use of sulfonylurea drugs to experience a “near coma” state, which users describe as “joyful” or “euphoric” [3, 5]. Such mind-altering effects are caused by the deliberate inducement of hypoglycemia or referred to as “factitious hypoglycemia” [6, 7]. A narrative review was conducted and designed to present a broad perspective on abuse or misuse of oral hypoglycemic agents, and describe its history and development in terms of how common it is and its public health implications. A structured literature search was conducted based on the question: what is currently known about liability of sulfonylureas to abuse? Search terms include sulfonylureas, oral hypoglycemic agents, glibenclamide, glyburide, different brand names, and “euphoria,” “high,” “hypoglycemic rush.” There was no restriction on date range, and all types of articles, including opinion pieces, were included.

In general, oral hypoglycemic agents are among the most benign and low-risk drugs in terms of potential abuse liability. However, on conducting this rapid review of web discussions and extant literature, we wish to draw the readership’s attention to this unique form of intoxicating and nonmedical intentional use of sulfonylurea drugs. We know that those interested in alternative ways of getting “high” are constantly in search for new alternatives that are available, cheap and legal, and replace those drugs which are harder to obtain, more expensive illicit drugs [8, 9]. For example, more unusual forms of pharmaceutical medicinal diversion

✉ Mayyada Wazaify  
m.wazaify@ju.edu.jo

<sup>1</sup> Department of Biopharmaceutics and Clinical Pharmacy,  
School of Pharmacy, The University of Jordan,  
Amman 11942, Jordan

<sup>2</sup> Public Health Institute, Liverpool John Moores University,  
Liverpool, UK

include those with little or no mental-altering effects such as bisoprolol, table salt, or menthol vapor rubs [8–10]. Hence, we report here on the case of abuse of sulfonylureas, whereby the reported intoxication effect is caused by adrenaline release [11, 12]. Adrenaline is responsible for the feeling of “rush” and contribution to dependence type behavior [11, 12].

Normally, the brain utilizes glucose as sole energy source, which makes it particularly sensitive to any decrease in blood glucose level. When blood glucose levels drop too low, the body tries to increase the amount of glucose available in the bloodstream by releasing hormones such as glucagon and epinephrine (also called adrenaline) that stimulate the release of glycogen from the liver [13]. Symptoms of hypoglycemia are caused by a combination of adrenaline release and low glucose in the brain. Adrenaline can cause anxiety, shaking, sweating, tachycardia, and emotional reactivity such as irritability, anger and tears, “brain fog,” fatigue, and insomnia [14]. These symptoms are often called the “warning signs” of hypoglycemia [13]. Lack of glucose to the brain can cause difficulties in concentration, blurred vision, slurred speech, lack of coordination, headaches, dizziness, and drowsiness. Hypoglycemia can also cause changes in emotions and mood. Feelings of nervousness and irritability, becoming argumentative, showing aggression, and crying are common, although some people experience euphoria and giddiness [14]. “Factitious hypoglycemia” occurs secondary to the surreptitious use of insulin or insulin secretagogues (sulfonylureas, meglitinides). It can be differentiated from fasting hypoglycemia caused by hyperinsulinaemia or injection of insulin, by an elevated (> 1.0) molar ratio of insulin to C-peptide [15]. When sulfonylurea preparations are consumed, the only way of distinguishing factitious hypoglycemia from insulinoma is by determining the drug in serum and urine [14].

We conducted a rapid assessment of web discussions and review of extant literature which describe this unique form of pharmaceutical medicinal abuse whereby consumers deliberately ingest large doses of glibenclamide (also known as Glyburide) of up to 50 mg at once to cause hypoglycemia and induce associated euphoric effects [6, 7, 16]. We note that the maximum daily dose ranges between 12 mg (micronized form) to 20 mg (standard glibenclamide) [17]. Several cases of deliberate inducement of hypoglycemia [6, 7, 16] described varied reasons for such excessive consumption, either to experience drug-induced euphoria [16] or in seeking attention caused by Munchausen syndrome [18]. Of note are that case reporting occurs in the majority in medical personnel, diabetics, or members of their family [14, 16]. There are several factors contributing to such increased risk of drug abuse among medical personnel, such as emotional stress at work and easy access to drugs [19]. In addition, healthcare professionals’ overconfidence may lead them to

believe that their medical competency will prevent problems relating to acute intoxication and misuse of such drugs [19]. A survey of 60 adolescents (12–20 years old) with type 1 diabetes mellitus revealed a 36.7% prevalence of substance (alcohol, tobacco, illicit drugs) use and 19% reported insulin misuse [20]. In this study, self-harm intent was reported by one-third of insulin misusers. Substance use and insulin misuse were not related to glycemic control or diabetes self-management behaviors [20].

Despite the low case reporting, web discussions register an interest in “factitious hypoglycemia” as evidence by the following comments: “I like the feeling. until it starts getting crazy intense, then it’s like I guess I should do something about this,” “mild hypoglycemia feels good to me. I feel like I have been day drinking,” “I know a lot of people describe having a hypo like being drunk, but at least you know why you’re drunk.” “I bet if there was a way to safely get your levels down to a hypo level and keep them there people would use it as a drug” [5].

Hence, we wish to draw attention to this unique form of pharmaceutical medicinal abuse for intoxication purposes, and the need for health professional awareness of vigilance for this form of diversion and patient misuse of their drugs. In addition, medical and pharmacy practitioners are advised to be aware of symptomatology of “factitious hypoglycemia” and the need for pharmacovigilance.

**Funding** None.

**Conflicts of interest** None.

## References

1. Suusman KE. The use and abuse of oral hypoglycemic agents. *Rocky Mt Med J.* 1967;64(2):56–9.
2. Horwitz DL. Factitious and artifactual hypoglycemia. *Endocrinol Metab Clin N Am.* 1989;18(1):203–10.
3. Brown A. Feeling euphoric on a low-carb diet? The effect on your brain is similar to an illicit drug. The conversation website. 2017. <http://theconversation.com/feeling-euphoric-on-a-low-carb-diet-the-effect-on-your-brain-is-similar-to-an-illicit-drug-76303>. Accessed 2 July 2018.
4. Hughes GF, McElnay JC, Hughes CM, McKenna P. Abuse/misuse of non-prescription drugs. *Pharm World Sci.* 1999;21:251–5.
5. Anonymous. Feeling some sort of high or euphoria from hypoglycemia. Reddit website. 2016. [https://www.reddit.com/r/diabetes/comments/4snzwp/feeling\\_some\\_sort\\_of\\_high\\_or\\_euphoria\\_from/](https://www.reddit.com/r/diabetes/comments/4snzwp/feeling_some_sort_of_high_or_euphoria_from/). Accessed 24 June 2018.
6. Marchetti P, Faloppa C, Zappella A, Navalesi R. A case of factitious hypoglycemia with unusual presentation. *Minerva Med.* 1988;79(12):1101–3.
7. Svirski B, Edoute Y. Sulfonylurea-induced factitious hypoglycemia. *Harefuah.* 1996;130(10):678–80.
8. Madae’ en S, Bostamy B, Jaber D, Wazaify M. Death of a middle-aged man after long term abuse of a combination anticholinergic, beta blockers and narcotic drugs: a suspected Münchausen syndrome case report. *J Addict Neuropharmacol.* 2015;2(1):7–9.

9. Jaber D, Al-Awwa I, Wazaify M. Multiple prescription drug abuse and salt craving in a psychotic patient: a case report from a teaching hospital in Jordan. *Int J High Risk Behav Addict*. 2015;4(3):e22449.
10. Blackwood GW. Severe psychological disturbance resulting from abuse of nasal decongestants. *Scott Med J*. 1982;27:175–6.
11. Schmidt KT, Weinshenker D. Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors. *Mol Pharmacol*. 2014;85(4):640–50.
12. Zaniwska M, Filip M, Przegalinski E. The involvement of norepinephrine in behaviors related to psychostimulant addiction. *Curr Neuropharmacol*. 2015;13(3):407–18.
13. Hieronymus L, O'Connell B. Understanding hypoglycemia. Diabetes self-management. 2017. <https://www.diabetesselfmanagement.com/managing-diabetes/blood-glucose-management/understanding-hypoglycemia/>. Accessed 24 June 2018.
14. Siegel EG, Mayer G, Nauck M, Creutzfeldt W. Factitious hypoglycemia caused by taking a sulfonylurea drug. *Dtsch Med Wochenschr*. 1987;112(41):1575–9.
15. Lebowitz MR, Blumenthal SA. The molar ratio of insulin to C-peptide: an aid to the diagnosis of hypoglycemia due to surreptitious (or inadvertent) insulin administration. *Arch Intern Med*. 1993;153(5):650–5.
16. Hasche H, Bachmann W, Haslbeck M, Mehnert H. Hypoglycaemia factitia: three case descriptions. Self-inflicted hypoglycaemia (three cases). *Dtsch Med Wochenschr*. 1982;107(16):625–8.
17. Glyburide dosage. [www.Drugs.com](http://www.Drugs.com). <https://www.drugs.com/dosage/glyburide.html>. Accessed 14 Oct 2018.
18. Jermendy G. Factitious hypoglycemia–Munchausen syndrome in diabetes mellitus. *Orv Hetil*. 1995;136(1):31–3.
19. Kenna GA, Wood MD. Prevalence of substance use by pharmacists and other health professionals. *J Am Pharm Assoc*. 2004;44(6):684–93.
20. Snyder LL, Truong YK, Law JR. Evaluating substance use and insulin misuse in adolescents with type 1 diabetes. *Diabetes Educ*. 2016;42(5):529–37.

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.